TY - JOUR T1 - The Efficacy and Limitations of Postoperative Adjuvant Chemotherapy in Patients With Extrahepatic Cholangiocarcinoma JF - Anticancer Research JO - Anticancer Res SP - 2155 LP - 2161 DO - 10.21873/anticanres.13329 VL - 39 IS - 4 AU - KOSHIRO MORINO AU - SATORU SEO AU - TOMOAKI YOH AU - HIROTO NISHINO AU - KENYA YAMANAKA AU - KEN FUKUMITSU AU - TAKAMICHI ISHII AU - KOJIRO TAURA AU - HIDEAKI OKAJIMA AU - TOSHIMI KAIDO AU - SHINJI UEMOTO Y1 - 2019/04/01 UR - http://ar.iiarjournals.org/content/39/4/2155.abstract N2 - Background/Aim: The impact of adjuvant chemotherapy (AC) for extrahepatic cholangiocarcinoma (ECC) remains unclear. This study evaluated the efficacy and limitations of AC. Patients and Methods: Between 2006 and 2016, 106 patients with stage II-IV ECC who underwent curative resection with biliary tract reconstruction were retrospectively analyzed. Patients were divided into two groups: Those who received AC (n=57) and those who did not (n=49). Results: Fewer grade 3-4 complications were observed in the AC group compared to the non-AC group (38.6 vs. 61.2%, p=0.03). In the non-AC group, complications were the most frequent reason for omitting AC (n=21, including 13 with biliary fistula). In the AC group, the therapy completion rate was 56.1% and the main reason for discontinuation was adverse events (n=12, including six with cholangitis). AC was not associated with survival benefits (median survival: 50.4 vs. 37.3 months, p=0.916). Conclusion: AC for ECC might be inadequate as a standard strategy due to the low implementation and completion rates because complications often hamper administration. ER -